Ki-1 Antigen

"Ki-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of the Ki-1 antigen in hematopoietic malignancies make it clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.

Descriptor ID	D017730
MeSH Number(s)	D12.776.543.750.705.852.760.072 D23.050.285.025 D23.101.140.055
Concept/Terms	Ki-1 Antigen Ki-1 Antigen Antigen, Ki-1 Ki 1 Antigen CD30 Antigens Antigens, CD30 Ber-H2 Antigen Antigen, Ber-H2 Ber H2 Antigen TNFRSF8 Receptor Receptor, TNFRSF8 Antigens, Ki-1 Antigens, Ki 1 Ki-1 Antigens Ki 1 Antigens Tumor Necrosis Factor Receptor Superfamily, Member 8 CD30 Antigen Antigen, CD30 Ber-H2 Antigens Antigens, Ber-H2 Ber H2 Antigens

Below are MeSH descriptors whose meaning is more general than "Ki-1 Antigen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Immunologic [D12.776.543.750.705]
Receptors, Cytokine [D12.776.543.750.705.852]
Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
Ki-1 Antigen [D12.776.543.750.705.852.760.072]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Neoplasm [D23.050.285]
Ki-1 Antigen [D23.050.285.025]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Ki-1 Antigen [D23.101.140.055]

Below are MeSH descriptors whose meaning is related to "Ki-1 Antigen".

Below are MeSH descriptors whose meaning is more specific than "Ki-1 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ki-1 Antigen" by people in this website by year, and whether "Ki-1 Antigen" was a major or minor topic of these publications.

Bar chart showing 20 publications over 13 distinct years, with a maximum of 4 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2006	1	1	2
2007	1	1	2
2009	0	1	1
2012	1	0	1
2013	1	0	1
2014	2	0	2
2016	0	1	1
2018	1	0	1
2019	2	0	2
2020	0	1	1
2021	0	4	4
2022	0	1	1
2024	0	1	1

Below are the most recent publications written about "Ki-1 Antigen" by people in Profiles.

Uttam P, Gupta RK. Primary leptomeningeal CD30 positive diffuse large B cell lymphoma disguise as meningioma in a young adult: a case report. Int J Neurosci. 2025 Apr; 135(4):428-433.

View in: PubMed
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Tr?mper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022 10 11; 6(19):5550-5555.

View in: PubMed
Hong J, Johnson WT, Kartan S, Gonsalves AS, Fenkel JM, Gong JZ, Porcu P. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). Curr Oncol. 2021 12 02; 28(6):5067-5072.

View in: PubMed
Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro B. A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV?+?lymphomas. Leuk Lymphoma. 2021 12; 62(14):3493-3500.

View in: PubMed
Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021 06 01; 106(6):1705-1713.

View in: PubMed
Nizamuddin I, Galvez C, Pro B. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. Semin Hematol. 2021 04; 58(2):85-94.

View in: PubMed
Allen PB, Pro B. Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes. Curr Oncol Rep. 2020 04 16; 22(5):44.

View in: PubMed
Barta SK, Gong JZ, Porcu P. Brentuximab vedotin in the treatment of CD30+ PTCL. Blood. 2019 12 26; 134(26):2339-2345.

View in: PubMed
Kartan S, Johnson WT, Sokol K, Alpdogan O, Gru AA, Nikbakht N, Porcu P. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin. Chin Clin Oncol. 2019 Feb; 8(1):3.

View in: PubMed
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018 05 10; 131(19):2120-2124.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement